Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MNC-686 is a preclinical-stage live biotherapeutic product (LBP) developed by MoonBio (慕恩生物) for the treatment of solid tumors. As a microbiome-based therapy, it utilizes live microorganisms designed to modulate the gut microbiome and stimulate anti-tumor immune responses. The asset is currently part of MoonBio's tumor immunology pipeline and is undergoing IND-enabling studies or preclinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MNC-686.